![Talha Badar: A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia](https://oncodaily.com/pub/uploads/2024/03/download-19-1-1280x1120.jpg)
Photo taken from Talha Badar/X
Apr 1, 2024, 23:39
Talha Badar: A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
Talha Badar, Hematologist/Oncologist at Mayo Clinic, shared a post on X/Twitter:
“A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
3+3 model with 4 INO dose levels: 0.3 mg/m2, 0.4 mg/m2, 0.5 mg/m2, and 0.6 mg/m2.
19 patients treated, dose-limiting toxicity (DLT) was thrombocytopenia.”
View the article attached to the post.
Source: Talha Badar/X